Objective: To delineate the developmental and progressive neurodegenerative features in 9 young adults with the atypical form of Chediak-Higashi disease (CHD) enrolled in a natural history study.
Chediak-Higashi disease (CHD; OMIM #214500) is a rare, autosomal recessive disorder with hematologic, pigmentary, and neurologic manifestations caused by biallelic pathogenic variants in the lysosomal trafficking regulator gene LYST. 1 Typical patients with CHD present with immunodeficiency and hemophagocytic lymphohistiocytosis (HLH), or the accelerated phase, 2, 3 along with variable degrees of bleeding, due to a delta storage pool deficiency of platelets, and oculocutaneous albinism. 4 Without therapy, children with classical CHD die of infections or from complications of HLH in the first decade. Bone marrow transplantation (BMT) prevents both of these outcomes, but does not stop the progression of neurologic deficits. 5 The neurologic involvement is characterized by subtle and nonspecific early neurodevelopmental issues including learning and behavioral deficits in childhood followed in early adulthood by a progressive neurodegeneration with varying degrees of cerebellar dysfunction, peripheral neuropathy, spasticity, dystonia, parkinsonism, impaired cognition, and premature death.
Adults with mild forms of CHD, despite harboring biallelic LYST variants, may escape early detection and consideration for BMT, because early life-threatening infections, bleeding, and HLH complications are muted. 7, 8 Nevertheless, such patients develop striking neurologic declines that may not be recognized as part of the CHD phenotype. Here, we review the natural history and the spectrum of neurologic involvement in 9 mildly affected adult patients with CHD, including their history, clinical, brain MRI, electrophysiologic, molecular, and cell biological findings. Laboratory investigations. Specialized laboratory investigations included monitoring for HLH, peripheral blood smears to confirm the presence of giant inclusions within neutrophils, microscopic hair examination, and whole mount electron microscopy of platelets to quantify dense bodies.
Neurophysiology. Nerve conduction studies were performed mainly on the median and sural sensory nerves and the peroneal and median motor nerves. Measurements used standard methodology with a Nicolet Viking Select machine (Cardinal Health, Dublin, OH) and were compared to department-based normative values. 9 Needle EMG was performed using a concentric needle and filter settings of 2K-10K with spontaneous and motor unit activity recorded according to standard methodology.
MRI.
The standard MRI examination of the brain consisted of sagittal T1-weighted, axial T2-weighted, axial T1-weighted, axial diffusion tensor, postcontrast axial T1-weighted, postcontrast axial fluid-attenuated inversion recovery, and postcontrast sagittal 3D T1-weighted images; 2 patients had similar examinations without administration of contrast material, and one patient was not scanned due to intense claustrophobia. The field strength was either 1.5T or 3T. We used elements of previously published metrics of posterior fossa traits to evaluate the sagittal configuration of the posterior fossa. 10 A superior cerebellar vermis angle was measured as the intersection of 2 line segments, one segment originating at the opening of the aqueduct into the fourth ventricle to the vein of Galen and the other projecting from the vein of Galen through the straight sinus into the torcula herophili. This angle was measured after reformatting the 3D T1-weighted images into an exact midsagittal plane, as defined by the plane of the falx cerebri. Measurements in patients were compared against sex-matched normal controls (in a 2:1 ratio) enrolled in other research protocols who had undergone similar imaging studies that included axial or sagittal 3D T1-weighted images.
Cells. Primary dermal fibroblasts were cultured from a forearm skin biopsy, as described. 8, 11 Cell culture conditions are described in the e-Methods on the Neurology ® Web site at Neurology.org. Molecular and cellular studies. Biallelic variants in LYST were identified in every patient (figure e-1A) except CHD-5, who was heterozygous for a novel missense variant; a second variant could not be detected. However, gDNA (derived from fibroblasts) sequencing showed 2 variant peaks of equal intensity (figure e-1B, arrow), indicating the presence of equal allelic amounts of DNA. In contrast, cDNA (derived from fibroblast mRNA) sequencing showed a higher intensity band for the variant missense allele (T) compared to the normal allele (G) (figure e-1B), indicating that the normal allele may carry a cryptic variant (deep intronic, or 39 or 59 UTR) causing mRNA decay. In fact, qPCR showed a significant reduction (63%-69%) of LYST mRNA using 3 different probes (p , 0.0001) (figure e-1B).
The pathogenicity of the 6 missense variants in our patients was examined using a 59 nuclease allelic discrimination (TaqMan) assay. None of these LYST variants was present in a DNA panel of 100 healthy individuals, indicating they are not common polymorphisms. Querying the ExAC databases of whole exome data revealed that most of the LYST variants were not present, and a few variants had very small allele frequencies (p , 0.0001), where none were homozygotes. In addition, the deleteriousness of the missense variants was assessed using 3 analysis programs, SIFT, PolyPhen-2, and Align-GVGD. All variants except p.E2810K were deemed damaging by all 3 programs. SIFT predicted p.E2810K to be tolerated, while PolyPhen-2 considered it possibly damaging and Align-GVGD predicted it to be deleterious.
The molecular alterations in our patients with mild CHD translated into reduced LYST protein expression in their cultured fibroblasts. We used CHD-4 (early-onset CHD, harboring deleterious variants p.R514X and p.F3298SfsX6) 12 Cultured fibroblasts from patients with CHD. The cellular phenotype of the patients with CHD reflected the severity of their molecular defects. In general, CHD cells have enlarged lysosomes and lysosome-related organelles (LROs) in various cell types such as fibroblasts, melanocytes, and polymorphonuclear leukocytes. 8, 13 We previously established that the size of lysosomes and LROs correlated with the severity of the disease, 8 and we found this to be true for the lysosomes in fibroblasts of our atypical CHD cases (figure 2B). We included previously described CHD-4 (classical CHD) and CHD-6 (mild late-onset CHD) for comparison. 8 CHD-4 fibroblasts exhibited giant lysosomes clustered around the nucleus while CHD-6 fibroblasts had a mixture of normal and slightly enlarged lysosomes in the perinuclear and peripheral areas. CHD-5 fibroblasts exhibited a cellular phenotype between that of CHD-4 and CHD-6 cells, with enlarged lysosomes in the perinuclear area and normal-sized lysosomes in the periphery. CHD-17 and CHD-18 closely resembled the cellular phenotype of control fibroblasts, with normal-sized lysosomes distributed in the perinuclear and peripheral regions.
Clinical neurology. All 9 patients exhibited developmental impairment manifested by learning disabilities (table 2) . Full-scale IQ (FSIQ) at baseline NIH visit evaluated using either the Wechsler Abbreviated Table 1 Clinical and molecular characteristics of atypical Chediak- 15 varied from 64 to 95, with an average baseline FSIQ of 80. Six patients had cerebellar signs, largely limb dysmetria, and 4 had parkinsonism; 3 were L-dopa responsive, and 2 displayed "on-off" fluctuations and peak-dose dyskinesia. Three patients had a mild postural tremor, 7 displayed weakness, and 4 had subtle sensory deficits manifesting as loss of distal vibratory sensation. Plantar responses were extensor in 4 patients, and all had absent or decreased deep tendon reflexes in the lower extremities, reflecting concurrent central and peripheral nervous system involvement. Two patients, both with parkinsonism, experienced active vivid dreaming clinically suggestive of REM sleep behavior disorder (RBD).
Brain imaging. MRI examinations revealed 1 patient with mild cerebral atrophy, 1 with mild cerebellar atrophy, 2 with mild cerebral and cerebellar atrophy, and 1 with moderate cerebral and cerebellar atrophy ( figure 3, E, F, and I) . In general, atrophy correlated with longer disease duration, more severe cognitive disabilities, or motor dysfunction. There were no supratentorial focal lesions, heterotopia, structural defects, or white matter signal abnormalities.
However, a group-specific morphologic variation in the configuration of the posterior fossa was observed in midsagittal images. The angle enclosing the superior cerebellar vermis was more acute in patients with CHD (mean 64°, range 52°-79°) (figure 3, A-F) than in age-and sex-matched controls (mean 86°, range 72°-97°), with p 5 0.00002 by 2-tailed heteroscedastic t test.
Electrophysiology. Seven patients underwent studies of nerve conduction and needle EMG; 5 had follow-up studies within 1-2 years. Table e-1 gives the initial study values, as well as 1-and 2-year follow-up values when available. At baseline, 2 patients had no detectable sural responses and 3 patients had low responses. Median nerve sensory response was low in one patient. For the motor nerves, one patient had a low peroneal response. All patients had normal median motor responses. The conduction velocities were all normal except for the median sensory and peroneal motor response in CHD-20, likely related to axonal loss and not in the demyelinating range. Needle EMG was performed in proximal and distal leg muscles in 6 patients. Three patients had acute or chronic neurogenic changes in the distal leg muscles, although one individual had no evidence of a neuropathy by nerve conduction studies. Two patients had electrodiagnostic evidence of an axonal sensorimotor polyneuropathy. Three individuals had an axonal sensory polyneuropathy.
On longitudinal follow-up, after 2 years, 2 individuals had developed an axonal neuropathy by nerve conduction studies. One patient also had a very low median motor response, but a limited electrodiagnostic study could not further define the cause. Only 2 patients had repeat EMG studies of 2 leg muscles; both showed progressive neurogenic changes that could be associated with additional motor neuron pathology.
DISCUSSION Among the ;500 cases of CHD reported, 16 genotype and phenotype correlate well.
7,8,17
In general, patients with classical CHD have 2 severe/ pathogenic LYST variants, while mildly affected individuals have one severe and one milder variant (e.g., missense). While LYST protein expression in cultured fibroblasts reflects the severity of the nonneurologic aspects of the disease (figure 2A), 11 the neurologic complications of CHD affect all patients without regard to the severity of their LYST variants.
LYST contains 3,801 amino acids, has a molecular weight of 430 kDa, and possesses ARM/HEAT repeat motifs that mediate membrane interactions and WD-40 repeats that function in protein interactions. 18 Adjacent to the WD-40 repeats is the amino acid sequence WIDL, together characterizing the Beige and Chediak (BEACH) group of proteins. 16, 18 LYST is widely expressed, including brain and bone marrow. LYST functions in trafficking lysosomes and regulating lysosomal morphology 16 ; the absence of LYST results in reduced lysosome fission without altering fusion, and overexpression of LYST results in a faster rate of lysosome fission. 19 CHD fibroblasts have giant vesicles that stain with LRO markers, clustering in the perinuclear cytoplasm, and fail to distribute normally into the periphery of cells.
The bloated lysosome-like organelles of CHD cells account for many of the manifestations of the disease. 20 Enlarged melanosomes in melanocytes move poorly along dendritic processes, and skin melanosomes cannot transfer melanin to surrounding keratinocytes, 4, 8, 20 resulting in hypopigmentation. The trafficking defect in CHD megakaryocytes results in absent or deficient platelet dense bodies, impairing the secondary aggregation response and resulting in bruising and mucous membrane bleeding. 20 In dendritic cells, giant lysosomes cannot migrate to and ingest pathogens, accounting for susceptibility to infections. The cause of the accelerated phase in CHD could be related to defective trafficking of perforin and, consequently, impaired apoptosis induced by lymphocytic cells.
The basis for nervous system involvement in CHD remains enigmatic. We do not know if progressive neurodegeneration emerges from the accumulation of undigested substrate in giant lysosomes, from impaired LRO trafficking along neuritic processes of Purkinje cells, corticospinal neurons, anterior horn cells, and other neuronal populations, or from dysfunctional vesicle incorporation into membranes.
In an early phase of CHD, features of developmental delay, learning difficulties, or attention deficit/hyperactivity disorder are nearly universal and reflect a developmental disturbance, supported by our finding of structural variations in the configuration of the posterior fossa. This nonspecific abnormality likely reflects variable degrees of cerebellar hypoplasia, especially in the midline cerebellum. We found similar MRI findings in all patients with CHD (including infants) prior to any hematologic complications compared to patients with classical CHD who had undergone BMT (unpublished observation).
A second phase of the illness appears around late adolescence, and manifests as a gradual and progressive neurologic decline. Progressive atrophic MRI changes in the cerebrum and cerebellum correlate with clinical worsening and increased disability. Generally, mild and nonspecific incoordination appears at school age, while well-defined midline cerebellar dysfunction and limb dysmetria, common features in mild CHD, occur in early adulthood. LYST variants in humans and in a missense Lyst I3618R murine model of CHD 21 appear to target Purkinje cells. Young adults with CHD have diminished or absent deep tendon reflexes resulting from a length-dependent, predominantly axonal polyneuropathy, commonly presenting as foot drop. Once present, progression occurs rapidly. Long tract signs, including spasticity and extensor plantar responses, are common but often obscured by weakness and atrophy associated with the coexisting peripheral neuropathy. In late stages, individuals lose the ability to ambulate and perform activities of daily living. We speculate that LYST dysfunction uncovers vulnerabilities in membrane repair, bioenergetics, vesicular trafficking, and cytoskeleton maintenance. In vitro studies demonstrate failure of cultured melanocytes from patients with CHD to properly traffic and release their pigment cargo to the extracellular space. 8 Both human CHD cells and those of the beige murine CHD model have defective lysosomal exocytosis and plasma membrane repair 22 ; these deficiencies likely contribute to neuronal degeneration and neurologic dysfunction.
CHD may present as parkinsonism. Other patients may experience limb dystonia. Four of our patients, and others in the literature, [23] [24] [25] [26] [27] have levodoparesponsive parkinsonism not unlike Parkinson disease (PD). 28 Two of our patients undergoing L-dopa replacement therapy for longer than 3 years experienced "on-off" fluctuation and L-dopa-induced dyskinesia consistent with a progressive presynaptic dopaminergic deficit. Two patients experienced RBD, a condition long regarded as an early feature of synucleinopathies, suggesting that LYST dysfunction may also influence the proteosomal degradation system and autophagy. LRO dysfunction occurs in several monogenic forms of PD, 29 most notably in Gaucher disease. Reduced vesicle fission in CHD is likely to adversely affect other neuronal processes such as vesicular packaging of dopamine, which might contribute to neurodegeneration. 30, 31 While classical hematologic and pigmentary features of CHD are recapitulated in the beige mouse model due to deletions within Lyst, 32 the neurologic characteristics of mild CHD are best exemplified in another CHD murine model with a homozygous Lyst I3618R missense variant. These animals, with a silvery gray coat and prolonged bleeding, have no evidence of ocular albinism, blood cell dysmorphology, susceptibility to infection, or development of HLH. 21 Instead, they have an age-dependent neurologic phenotype consisting of late-onset cerebellar dysfunction and motor coordination deficits. Their brains revealed no abnormalities in young mice, but by 5 months, giant inclusions appeared, primarily in the cerebellum. The Purkinje cells are laden with giant vesicular inclusions at the base of their dendritic arborization. With advancing age, these changes evolved into substantial Purkinje cell degeneration. 21 For decades, the neurologic findings of CHD were masked by the disease's early, fatal infections and HLH. Now, bone marrow transplantation and mildly affected individuals are making the neurologic aspects of CHD apparent. Ascertainment remains challenging for patients with mild disease, largely because of the vague, varied, and nonspecific nature of their neurologic phenotypes. Neurologists should suspect CHD when they encounter individuals with subtle neurologic signs and any combination of skin or ocular pigment dilution, bleeding tendency, or unusual infectious history. Given their early learning disabilities, cognitive issues, and soft neurologic findings, many young patients with mild CHD may carry static diagnoses such as developmental delay or cerebral palsy. However, the neurologic involvement of CHD progresses inexorably. For some patients with CHD with parkinsonism, standard dopaminergic therapy produces substantial, life-changing benefits, at least in the short term. For others, proper adaptive equipment, vocational counseling, and physical and occupation rehabilitation can improve quality of life. Finally, our patient CHD-20 is a powerful reminder that the accelerated phase can occur at any age, and patients should be closely monitored for any suggestion of HLH.
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